Skip to content

Prostatectomies Using Einstein Vision® 3D

Prospective, Multi-centre, Non-interventional Trial on Laparoscopic Radical PROSTatectomies Using EinsteinVISion® 3D Visualization System

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02991794
Acronym
PROSTEVIS
Enrollment
156
Registered
2016-12-14
Start date
2017-05-19
Completion date
2020-11-06
Last updated
2021-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Carcinoma

Keywords

prostatectomy, laparoscopy, 3D visualization, learning curve, anastomosis

Brief summary

The aim of the study is collecting clinical data on the learning curve of different surgeons using the EinsteinVision® 3D visualization system in laparoscopic radical prostatectomies.

Interventions

DEVICEEinsteinVision 3D visualization system

Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.

Sponsors

Aesculap AG
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing planned radical prostatectomy prostatectomy because of histologically proven prostate cancer using EinsteinVision® * Written informed consent * Age ≥ 18 years

Exclusion criteria

* Previous TURP (= transurethral resection of the prostate) * Previous operations on the sigmoid colon or rectum (e.g. because of carcinoma, perforation, diverticulum) * BMI \> 35 kg/m² * Participation in another clinical study * Representation by a legal guardian or under involuntary commitment

Design outcomes

Primary

MeasureTime frameDescription
Time needed to perform the vesicourethral anastomosis using EinsteinVision® in a group of different surgeons [min. sec.]Intraoperativelylearning curve of different surgeons with diverse level of experience using EinsteinVision® 3D visualization system

Secondary

MeasureTime frameDescription
Intraoperative blood loss [ml]Intraoperatively
Intraoperative blood transfusions [quantity]Intraoperatively
Postoperative blood transfusions [quantity]Postoperatively
Intraoperative incidence of complications [percentage]Intraoperatively(e.g. bleedings, Trauma of ureter)
Postoperative incidence of complications [percentage]During stay in Hospital (5-12 days postoperatively)(e.g. Ileus, venous thrombo-embolic events, wound infection, bleedings)
Surgeon's experience with different operation methods and application systemsAfter first intervention for each hospital and after study completion, an average of 1 year laterusing a questionnaire at the beginning (First Patient In) and the end of the study (Last Patient In)
Operation time [min.]Intraoperatively
Patient's quality of lifePreoperatively, 5-12 days postoperatively, 3 months, 6 months, 12 months postoperativelyPre- and postoperative patient's quality of life using the questionnaire EQ-5D-5L The following dimensions are assessed: * Mobility * Self-care * Usual activities * Pain / discomfort * Anxiety / depression * Health
Incontinence after catheterization [percentage]During stay in Hospital (5-12 days postoperatively)
Postoperative hospital stay [days]During stay in Hospital (5-12 days postoperatively)
Return to erectile function [percentage]12 months
Return to continence function [percentage]12 months
Incontinence pads/pants per day [quantity]5-12 days postoperatively, 3 months, 6 months, 12 months postoperatively
Postoperative patient satisfaction5-12 days postoperatively, 3 months, 6 months, 12 months postoperativelyusing a 10-point assessment level (1 = completely dissatisfied, 10 = completely satisfied)
Intraoperative usability of the deviceIntraoperativelyusing a questionnaire containing different dimensions and a 5-point assessment level (Likert Scale: 1 = excellent, 5 = unacceptable). The following dimensions are assessed: * Control * Expenditure of energy * Image quality * Overall satisfaction

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026